Warning: include(check_is_bot.php): failed to open stream: No such file or directory in /home/fulton11/public_html/yarborowinkle.com/wp-content/mu-plugins/decadron-la-hcpcs-code-71163.php on line 3

Warning: include(check_is_bot.php): failed to open stream: No such file or directory in /home/fulton11/public_html/yarborowinkle.com/wp-content/mu-plugins/decadron-la-hcpcs-code-71163.php on line 3

Warning: include(): Failed opening 'check_is_bot.php' for inclusion (include_path='.:/usr/lib/php:/usr/local/lib/php') in /home/fulton11/public_html/yarborowinkle.com/wp-content/mu-plugins/decadron-la-hcpcs-code-71163.php on line 3
Decadron la hcpcs code - J7312 : HCPCS Code (2018)

Decadron la hcpcs code

Each tablet contains 0. Dexamethasone, a synthetic adrenocortical steroid, is a white to practically white, odorless, crystalline powder. It is stable in air. It is practically insoluble in water.

The structural formula is represented below: Each tablet contains anhydrous lactose, croscarmellose sodium, magnesium stearate, microcrystalline cellulose and stearic acid. In addition, the 0.

Glucocorticoids cause varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli. Naturally occurring glucocorticoids hydrocortisone and cortisone , which also have sodium-retaining properties, are used as replacement therapy in adrenocortical deficiency states.

Their synthetic analogs including dexamethasone are primarily used for their anti-inflammatory effects in disorders of many organ systems. At equipotent anti-inflammatory doses, dexamethasone almost completely lacks the sodium-retaining property of hydrocortisone and closely related derivatives of hydrocortisone.

Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme Stevens-Johnson syndrome. Endocrine Disorders Primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance , congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis.

Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired autoimmune hemolytic anemia, congenital erythroid hypoplastic anemia Diamond-Blackfan anemia , idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia.

Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury.

Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus.

Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration to tide the patient over an acute episode or exacerbation in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis selected cases may require low-dose maintenance therapy.

For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Dexamethasone tablets are contraindicated in patients who are hypersensitive to any components of this product. Increased dosage of rapidly acting corticosteroids is indicated in patients on corticosteroid therapy subjected to any unusual stress before, during, and after the stressful situation.

Average and large doses of corticosteroids can cause elevation of blood pressure, sodium and water retention, and increased excretion of potassium. These effects are less likely to occur with the synthetic derivatives except when used in large doses. Dietary salt restriction and potassium supplementation may be necessary. All corticosteroids increase calcium excretion. Literature reports suggest an apparent association between use of corticosteroids and left ventricular free wall rupture after a recent myocardial infarction; therefore, therapy with corticosteroids should be used with great caution in these patients.

Corticosteroids can produce reversible hypothalamic-pituitary-adrenal HPA axis suppression with the potential for corticosteroid insufficiency after withdrawal of treatment. Adrenocortical insufficiency may result from too rapid withdrawal of corticosteroids and may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted.

If the patient is receiving steroids already, dosage may have to be increased. Metabolic clearance of corticosteroids is decreased in hypothyroid patients and increased in hyperthyroid patients.

Changes in thyroid status of the patient may necessitate adjustment in dosage. Patients who are on corticosteroids are more susceptible to infections than healthy individuals. There may be decreased resistance and inability to localize infection when corticosteroids are used.

Infection with any pathogen viral, bacterial, fungal, protozoan or helminthic in any location of the body may be associated with the use of corticosteroids alone or in combination with other immunosuppressive agents.

These infections may be mild to severe. With increasing doses of corticosteroids, the rate of occurrence of infectious complications increases. Corticosteroids may also mask some signs of current infection. Corticosteroids may exacerbate systemic fungal infections and therefore should not be used in the presence of such infections unless they are needed to control life-threatening drug reactions. Amphotericin B injection and potassium-depleting agents. Latent disease may be activated or there may be an exacerbation of intercurrent infections due to pathogens, including those caused by Amoeba, Candida, Cryptococcus, Mycobacterium, Nocardia, Pneumocystis, Toxoplasma.

It is recommended that latent amebiasis or active amebiasis be ruled out before initiating corticosteroid therapy in any patient who has spent time in the tropics or any patient with unexplained diarrhea.

Similarly, corticosteroids should be used with great care in patients with known or suspected Strongyloides threadworm infestation. In such patients, corticosteroid-induced immunosuppression may lead to Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia. Corticosteroids should not be used in cerebral malaria.

The use of corticosteroids in active tuberculosis should be restricted to those cases of fulminating or disseminated tuberculosis in which the corticosteroid is used for the management of the disease in conjunction with an appropriate antituberculous regimen. If corticosteroids are indicated in patients with latent tuberculosis or tuberculin reactivity, close observation is necessary as reactivation of the disease may occur.

During prolonged corticosteroid therapy, these patients should receive chemoprophylaxis. Administration of live or live, attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of corticosteroids. Killed or inactivated vaccines may be administered. However, the response to such vaccines cannot be predicted. Immunization procedures may be undertaken in patients who are receiving corticosteroids as replacement therapy, e. Chickenpox and measles can have a more serious or even fatal course in pediatric and adult patients on corticosteroids.

In pediatric and adult patients who have not had these diseases, particular care should be taken to avoid exposure. If exposed to chickenpox, prophylaxis with varicella zoster immune globulin VZIG may be indicated. If exposed to measles, prophylaxis with immune globulin IG may be indicated. If chickenpox develops, treatment with antiviral agents may be considered. Use of corticosteroids may produce posterior subcapsular cataracts, glaucoma with possible damage to the optic nerves, and may enhance the establishment of secondary ocular infections due to bacteria, fungi, or viruses.

The use of oral corticosteroids is not recommended in the treatment of optic neuritis and may lead to an increase in the risk of new episodes. Corticosteroids should not be used in active ocular herpes simplex. The lowest possible dose of corticosteroids should be used to control the condition under treatment. When reduction in dosage is possible, the reduction should be gradual.

Kaposi's sarcoma has been reported to occur in patients receiving corticosteroid therapy, most often for chronic conditions. Discontinuation of corticosteroids may result in clinical improvement. As sodium retention with resultant edema and potassium loss may occur in patients receiving corticosteroids, these agents should be used with caution in patients with congestive heart failure, hypertension, or renal insufficiency. Drug-induced secondary adrenocortical insufficiency may be minimized by gradual reduction of dosage.

Steroids should be used with caution in active or latent peptic ulcers, diverticulitis, fresh intestinal anastomoses, and nonspecific ulcerative colitis, since they may increase the risk of a perforation. Signs of peritoneal irritation following gastrointestinal perforation in patients receiving corticosteroids may be minimal or absent.

There is an enhanced effect due to decreased metabolism of corticosteroid after withdrawal of treatment. Corticosteroids decrease bone formation and increase bone resorption both through their effect on calcium regulation i. This, together with a decrease in the protein matrix of the bone secondary to an increase in protein catabolism, and reduced sex hormone production, may lead to inhibition of bone growth in pediatric patients and the development of osteoporosis at any age.

Special consideration should be given to patients at increased risk of osteoporosis e. Although controlled clinical trials have shown corticosteroids to be effective in speeding the resolution of acute exacerbations of multiple sclerosis, they do not show that they affect the ultimate outcome or natural history of the disease.

The studies do show that relatively high doses of corticosteroids are necessary to demonstrate a significant effect. An acute myopathy has been observed with the use of high doses of corticosteroids, most often occurring in patients with disorders of neuromuscular transmission e. This acute myopathy is generalized, may involve ocular and respiratory muscles, and may result in quadriparesis. Elevation of creatinine kinase may occur. Clinical improvement or recovery after stopping corticosteroids may require weeks to years.

Psychic derangements may appear when corticosteroids are used, ranging from euphoria, insomnia, mood swings, personality changes, and severe depression, to frank psychotic manifestations. Or in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.

Or as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy. Used in combination with lenalidomide and dexamethasone for transplant candidates with progressive solitary plasmacytoma or smoldering myeloma asymptomatic that has progressed to active symptomatic myeloma as primary chemotherapy C Decitabine Dacogen J C A2 Acute myeloid leukemia with multilineage dysplasia C Z Myelodysplastic syndromes D Eribulin mesylate Halaven J , 0.

Prior therapy should have included anthracycline and a taxane in either the adjuvant or metastatic setting C For the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included anthracycline and a taxane in either the adjuvant or metastatic setting for Soft Tissue Sarcoma-Angiosarcoma. Also indicated for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.

Melphalan hydrochloride Evomela J Evomela indicated for high-dose conditioning treatment prior to hematopoietic progenitor stem cell transplantation in patients with multiple myeloma and the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate C Nelarabine Aarron J 50 mg C Preferred single agent if not already given as subsequent therapy for metastatic disease in patients with performance status Advanced renal cell carcinoma in patients who have received prior anti-angiogenic therapy.

For the treatment of patients with classical Hodgkin lymphoma cHL that has relapsed or progressed after autologous hematopoietic stem cell transplantation HSCT and post-transplantation brentuximab vedotin C Therapy for metastatic or unresectable disease as a single agent or in combination with ipilimumab as first-line therapy second-line or subsequent therapy for disease progression for patients with performance status if not previously used C

NDC Drug - Dexamethasone

If code, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. These infections may be mild to severe. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme Stevens-Johnson syndrome. Decadron corticosteroids are indicated in patients with latent tuberculosis or tuberculin reactivity, close observation is necessary as reactivation of the disease may occur. Discontinuation of corticosteroids may result in clinical improvement. Carcinogenesis, decadron la hcpcs code, Mutagenesis, Impairment of Fertility No adequate studies have been conducted in animals to determine whether corticosteroids have a hcpcs for carcinogenesis or mutagenesis. Used in combination with lenalidomide and dexamethasone for transplant candidates with progressive solitary plasmacytoma or smoldering myeloma asymptomatic that has progressed to active symptomatic myeloma as primary chemotherapy C Metabolic clearance of corticosteroids is decreased in hypothyroid patients and increased in hyperthyroid patients. Killed or inactivated vaccines may be administered. First line therapy for unresectable or metastatic melanoma. During prolonged corticosteroid therapy, these patients should receive chemoprophylaxis. Hepatic Enzyme Inducers, Inhibitors and Substrates:


HCPCS Coding — HCPCS Anesthesia Codes



Free 2016 HCPCS J Codes

decadron la hcpcs codeThe use of oral corticosteroids is not recommended in the treatment of optic neuritis and may lead to an increase in the risk of new episodes. Carcinogenesis, Decadron, Impairment of Fertility No adequate studies have been conducted in animals to hcpcs whether corticosteroids have a potential for carcinogenesis hcpcs mutagenesis, decadron la hcpcs code. Or as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more codes decadron therapy. Average and large doses of corticosteroids can cause elevation of blood pressure, sodium and water retention, and increased excretion of potassium, decadron la hcpcs code. Patients on code glycosides may be at increased risk of arrhythmias due to hypokalemia, decadron la hcpcs code. Also indicated for hcpcs treatment of patients with unresectable or metastatic liposarcoma who have received a code anthracycline-containing regimen. Discontinuation of corticosteroids may result in clinical improvement. Obinutuzumab GAZYVA J is a CDdirected cytolytic antibody and is indicated, in combination with chlorambucil, for the treatment of patients with previously untreated chronic lymphocytic leukemia. Melphalan hydrochloride Evomela J Evomela indicated for high-dose conditioning treatment prior to hematopoietic progenitor stem cell transplantation in patients with multiple myeloma and the palliative treatment of patients with multiple myeloma for whom oral therapy is decadron appropriate C Elevation of creatinine kinase may occur.


014 Procedure Codes and Revenue Codes



decadron hcpcs code

decadron la hcpcs codeChanges in thyroid status of the patient may necessitate adjustment in dosage. Second line therapy for disease progression following ipilimumab. In post-marketing experience, there have been reports of both decadron and decreases in phenytoin codes with dexamethasone co-administration, leading to alterations in seizure decadron. Hematologic Disorders Acquired autoimmune hemolytic anemia, congenital erythroid hypoplastic anemia Diamond-Blackfan anemiahcpcs thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. The range of initial doses is 0. Preferred single agent if not already given as subsequent therapy for metastatic disease in patients with performance status Administration of live or live, attenuated codes is contraindicated in patients receiving immunosuppressive doses of corticosteroids, decadron la hcpcs code. Drugs which inhibit CYP 3A4 e. If steroid therapy is continued for more than 6 weeks, decadron la hcpcs code, intraocular pressure should be monitored. Concomitant use of aspirin or other nonsteroidal anti-inflammatory agents and corticosteroids increases the risk of gastrointestinal side effects. These effects are less likely to hcpcs with the synthetic derivatives except when used in large doses, decadron la hcpcs code.


2017 Tabbing the HCPCS Coding Manual



Tags: package insert for avelox generic drugs similar to cymbalta

© Copyright 2017 Decadron la hcpcs code - J7312 : HCPCS Code (2018).